Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Buys Path Labs for $6M

NEW YORK (GenomeWeb) – Cancer genetics testing firm NeoGenomics said on Tuesday it has acquired Path Labs for $6 million.

Doing business as Path Logic, Path Labs is headquartered in Santa Ana, Calif., and provides specialized anatomic pathology services to hospitals and physicians in Northern California. Its areas of expertise include renal pathology, dermapathology, women's health, and gastrointestinal and genitourinary pathology.

In 2013, it reported $10 million in revenues and employed 65 people. As part of the deal, NeoGenomics acquires Path Labs' main laboratory in West Sacramento and its satellite facilities in Santa Ana and Fresno.

Path Labs will operate as a wholly owned subsidiary of NeoGenomics and provide specialized anatomic pathology services for NeoGenomics' clinical trials and pathology clients, the Fort Myers, Fla.-based firm said.

NeoGenomics Chairman and CEO Douglas VanOort said in a statement that he anticipates realizing $3 million to $4 million of synergies from the deal "in a relatively short order" and that the transaction will be accretive within six months.

"With this expanded capability, both our clinical trial clients and our hospital and pathology-based clients will have access to an expanded product line and consulting expertise," he said.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.